Vancomycin therapeutic drug monitoring in patients on continuous renal replacement therapy: a retrospective study

• Published in: Journal of international medical research 2022-09, Vol.50 (9), p.3000605221126871-3000605221126871
• Main Authors: Liu, Yuyan, Jiang, Li, Lou, Ran, Wang, Meiping, Si, Quan
• Format: Article
• Language: English
• Subjects: Antibiotics; Drug dosages; Renal replacement therapy; Retrospective Clinical Research Report; Risk factors; Therapeutic drug monitoring
• ISSN: 0300-0605; 1473-2300
• DOI: 10.1177/03000605221126871

Objectives This study aimed to investigate vancomycin therapeutic drug monitoring (TDM) in patients on continuous renal replacement therapy (CRRT) and explore the risk factors for exceeding the target concentration. Methods This retrospective study enrolled patients aged ≥18 years who were admitted to the intensive care unit and treated with ≥3 intravenous vancomycin doses during CRRT, and who underwent vancomycin TDM. Demographic and other information were collected. Multivariate logistic regression was used assess the risk factors for exceeding the target concentration. Results Sixty-nine patients were included, and 40.6% patients underwent TDM. Additionally, 14.5% of patients reached the optimal concentration, and 87.5% of patients who exceeded the target received a daily dose adjustment. The cumulative dose of vancomycin and serum albumin were risk factors for exceeding the target concentration in patients on CRRT. Conclusions Patients on CRRT did not meet the optimal vancomycin management;